A brief recap of Genetics/Genomics news the week of Mar 22, 2019: Novogene, Hologic, Agilent, and Diagenode
Novogene's Chinese clinical lab will offer LifeMap's recently updated TGex next-generation sequencing data analysis and interpretation platform.
The firm's next-generation sequencing diagnostic test analyzes tumor samples from multiple genomic mutations that are targeted by therapies for non-small cell lung cancer.
The partners will develop next-generation sequencing-based tests for precision cancer treatment for the Asian market.
Researchers identified trait-related variants by sequencing more than 400 upland cotton accessions and nearly 250 representatives from two diploid Gossypium species.
The lab is located within Novogene's sequencing center at the Sacramento campus of the University of California, Davis.
The Chinese government has implemented clearer regulatory guidance for genomic tests and invested in both clinical testing and research, spurring growth.
The firms plan to focus on sample processing methods, workflow automation, algorithms, and database construction.
Novogene will validate Trovagene's proprietary urine collection and nucleic acid preservation device, NextCollect, and develop tests for the Chinese market.
The Genome Institute of Singapore will collaborate with the new center to develop applications related to cancer diagnosis and treatment stratification.
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.